Flanders Biotech cluster is situated in the heart of Belgium and comprises of the Flanders and Brussels areas. The cluster is considered a highly innovative and successful biotech cluster. Flanders Biotech Cluster is overseen by Flanders Bio and their mission is to develop the life science and biotechnology sector in the cluster and the wider area.
The Flanders Biotech cluster comprises of 13500km2 and houses 147 companies with active operations within the biotech cluster. Around 124 (84%) of these companies have research & development capabilities in the cluster. Of these companies, 69 (46%) companies are related to healthcare (red biotechnology), 15 (10%) companies in agriculture, 25 (17%) in industrial biotechnology and 38 (27%) companies are service providers. Within the cluster there are 5 leading research institutions including the University of Antwerp, Hasselt University and Vrije Universiteit Brussels. All the institutions have provided a considerable volume of ideas and talent into the local biotech cluster.
The Flanders Biotech cluster is thriving, with a total turnover in the cluster of around E2.9bn. Since 2005, there have been 6 Flemish biotech IPOs including most recently the regenerative medicine biotech Cardio3 Biosciences. Companies within the cluster have raised over E300m in funding from public offerings. Funding has also come in the form of government grants and private financing. Since 2007,companies have raised over E0.5bn in private funding. This capital has partly come from many of the venture capital companies in the cluster including; Capricorn Venture Partners, Thurja capital and Biotech Fonds Vlaanderen. The private funding provided has helped to fund some of the most innovative companies in the cluster including Amakem, Complix, Galapagos, Pronota, ar-GENX, Okapi Sciences, Ablynx and TiGenix. Ablynx, although now public, raised further funding this year to support the development of its antibody pipeline.
Alongside some of the innovative biotechs there are some global pharma companies present in the cluster. Some of the most notable examples are UCB, GSK Biologics, Janssen (J&J)... The blend of big pharma and innovative biotechs has led to an entrepreneurial culture in the cluster with many companies spinning out of local universities to set up in the cluster. Companies are ably supported by a network of finance companies and technology transfer offices including UGent Tech Transfer and KU Leuven. Further to this, companies are supported by a number of global and local service companies including Quintiles, PPD and The Clinical Company. For companies looking to begin clinical trials the cluster also offers a number of hospital sites including the internationally renowned Antwerp University Hospital.
Flanders Bio offers life science professionals a wealth of choices from innovative companies in rare diseases to global pharmaceutical companies. Flanders has a thriving biotech cluster and the continued support of Flanders Bio to help companies enter the cluster and develop has led to many innovative companies setting up home in the cluster. Liftstream believes that the expanding Flanders cluster is constantly enhancing its reputation worldwide, offering increasing opportunities for life science professionals.
For more information regarding the Flanders Biotech Cluster please follow the website below: